BERGENBIO TO PRESENT AT ABGSC SEMINAR
Bergen, Norway, 21[st] May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference: ABGSC Life Science Summit, virtual Date: 25 May Live presentation at 10.30hrs CET The presentation will be made available on the Company website: www.bergenbio.com/investors/presentations/ – END – About AXL AXL kinase is a cell membrane receptor and an essential mediator of the